HPLC analysis for simultaneous determination of atorvastatin and ezetimibe in pharmaceutical formulations

A simple, isocratic, and sensitive reverse phase high performance liquid chromatographic (RP-LC) method has been developed, for the first time, for quantitative determination of atorvastatin and ezetimibe in pharmaceutical formulations. Atorvastatin and ezetimibe were chromatographed using 0.01M ammonium acetate buffer (pH:3.0): Acetonitrile (50:50v/v) as mobile phase. The detection was monitored at 254nm. The retention times of ezetimibe and atorvastatin were 15.50 +/- 0.07 and 19.30 +/- 0.06, respectively. The linearity of the method was studied over the concentration range of 4-400 mu g/mL for atorvastatin and 5-500 mu g/mL for ezetimibe. The limit of detection for atorvastatin and ezetimibe were found as 1.25 mu g/mL and 1.48 mu g/mL, respectively. The proposed method was applied for the quantitative determination of atorvastatin and ezetimibe in commercial combination formulations.